The treatment of multiple sclerosis has made enormous progress thanks to highly effective disease-modifying therapies, in particular anti-CD20 antibodies. For most newly diagnosed patients, a life without disability is realistic. However, the focus is now shifting from preventing acute relapses to combating the insidious progression of disability. New approaches target cellular mechanisms in the CNS and the promotion of remyelination.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
You May Also Like
- Chronic hand eczema
Topical pan-JAK-i vs. systemic retinoid: head-to-head study
- Study report
Long-term data on CFTR modulators in children with cystic fibrosis
- Multiple sclerosis
Multiple sclerosis 2025: New strategies against progression and the role of microglia
- A syndrome between decompensation and chronification
Worsening Heart Failure
- Actinic keratosis
Field-directed therapy methods: what the European guideline recommends
Opicapon: double benefit for motor function and sleep in Parkinson’s disease
- Colorectal cancer
Is exercise better than medication?
- Itching in primary biliary cholangitis